![](/img/cover-not-exists.png)
Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
Gilbert, Jill, Le Tourneau, Christophe, Mehanna, Hisham, Fayette, Jerome, Goswami, Trishna, Emeribe, Ugochi, Jarkowski, Anthony, Melillo, Giovanni, Siu, Lilian LVolume:
3
Year:
2015
Language:
english
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1186/2051-1426-3-S2-P152
File:
PDF, 349 KB
english, 2015